VEGFA and hepatocellular carcinoma: Anti-angiogenic therapy combined with immunotherapy has been shown to promote vascular normalization, alleviate vascular endothelial growth factor (VEGF)-mediated immunosuppression, and enhance anti-tumor immune responses in patients with HCC and other malignancies [52,55,56,57].